Metformin and thyroid carcinoma incidence and prognosis: A systematic review and meta-analysis

被引:7
|
作者
Wang, Zikun [1 ]
Luo, Juhua [1 ]
Zhang, Yijia [2 ,3 ]
Xun, Pengcheng [1 ]
Chen, Zhongxue [1 ]
机构
[1] Indiana Univ Bloomington, Sch Publ Hlth, Dept Epidemiol & Biostat, Bloomington, IN 47405 USA
[2] Columbia Univ, Dept Obstet & Gynecol, Irving Med Ctr, New York, NY USA
[3] Columbia Univ, Dept Epidemiol, Irving Med Ctr, New York, NY USA
来源
PLOS ONE | 2022年 / 17卷 / 07期
关键词
DIABETIC-PATIENTS; CANCER-RISK; BREAST-CANCER; THERAPY; BIAS; METASTASIS; MORTALITY; EXPOSURE; MELLITUS; INSULIN;
D O I
10.1371/journal.pone.0271038
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Metformin has been suggested to reduce thyroid cancer incidence and to improve thyroid cancer prognosis. We aimed to evaluate the associations between metformin and thyroid cancer incidence and prognosis (metastasis/recurrence/progression-free survival). Cochrane Library, PubMed, ClinicalTrials.gov, and U.S. National Library of Medicine Clinical Trials were searched through the end of December 2021. Data were collected from original observational studies or clinical trials on the incidence or prognosis of thyroid carcinoma outcomes in type 2 diabetes mellitus (T2DM) patients with and without metformin use. Risk of bias in non-randomized studies of interventions (ROBINS-I) tool and Grading of Recommendations, and Assessment, Development and Evaluations (GRADE) approach were used to evaluate the risk of bias and quality of the body of evidence, respectively. In general, 4 studies were related to the thyroid cancer incidence, including 1,705,123 participants metformin users and non-users and yielding a total of 3,238 thyroid cancer events; 3 studies reported the prognosis of thyroid carcinoma based on a total of 4,972 individuals with primary thyroid carcinoma and comorbid type 2 diabetes, and the number of thyroid cancer prognosis cases ranged from 3 to 79. The overall risk of bias of the included studies ranged from moderate to serious. In the random-effects model, the summary relative risk (SRR) for thyroid cancer incidence was 0.743 (95% CI: 0.453-1.220; I-2 = 88.7%, low certainty) comparing metformin users to non-users; and SRR for the prognosis of thyroid cancer was 0.504 (95% CI: 0.178-1.430; I-2 = 57.5%, low certainty). Non-statistically significant negative associations between metformin use and incidence and prognosis of thyroid cancer were found in the current analysis, although the quantity and quality of the evidence were limited. Futher investigation is needed to evaluate the clinical benefits of metformin on thyroid cancer prevention and treatments.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis
    He, Kancheng
    Hu, Huating
    Ye, Senlin
    Wang, Haohui
    Cui, Rongrong
    Yi, Lu
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [2] The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis
    Kancheng He
    Huating Hu
    Senlin Ye
    Haohui Wang
    Rongrong Cui
    Lu Yi
    [J]. Scientific Reports, 9
  • [3] Association of metformin use with ovarian cancer incidence and prognosis: a systematic review and meta-analysis
    Shi, Jinghua
    Liu, Baoli
    Wang, Hongmei
    Zhang, Tie
    Yang, Libo
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (01) : 140 - 146
  • [4] Association of Multifocality With Prognosis of Papillary Thyroid Carcinoma A Systematic Review and Meta-analysis
    Kim, Hyeonkyeong
    Kwon, Hyungju
    Moon, Byung-In
    [J]. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2021, 147 (10) : 847 - 854
  • [5] PROGNOSIS OF DIFFERENTIATED THYROID CARCINOMA IN PATIENTS WITH GRAVES DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Mekraksakit, Poemlarp
    Rattanawong, Pattara
    Karnchanasorn, Rudruidee
    Kanitsoraphan, Chanavuth
    Leelaviwat, Natnicha
    Poonsombudlert, Kittika
    Kewcharoen, Jakrin
    Dejhansathit, Siroj
    Samoa, Raynald
    [J]. ENDOCRINE PRACTICE, 2019, 25 (12) : 1323 - 1337
  • [6] Association of metformin use and cancer incidence: a systematic review and meta-analysis
    O'Connor, Lauren
    Bailey-Whyte, Maeve
    Bhattacharya, Manami
    Butera, Gisela
    Hardell, Kaitlyn N. Lewis
    Seidenberg, Andrew B.
    Castle, Philip E.
    Loomans-Kropp, Holli A.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (04) : 518 - 529
  • [7] Thyroid dysfunction and cancer incidence: a systematic review and meta-analysis
    Thi-Van-Trinh Tran
    Kitahara, Cari M.
    de Vathaire, Florent
    Boutron-Ruault, Marie-Christine
    Journy, Neige
    [J]. ENDOCRINE-RELATED CANCER, 2020, 27 (04) : 245 - 259
  • [8] Hobnail Papillary Thyroid Carcinoma, A Systematic Review and Meta-Analysis
    Spyroglou, Ariadni
    Kostopoulos, Georgios
    Tseleni, Sofia
    Toulis, Konstantinos
    Bramis, Konstantinos
    Mastorakos, George
    Konstadoulakis, Manousos
    Vamvakidis, Kyriakos
    Alexandraki, Krystallenia, I
    [J]. CANCERS, 2022, 14 (11)
  • [9] RE: Association of metformin use and cancer incidence: a systematic review and meta-analysis
    Khouri, Charles
    Suissa, Samy
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (08): : 1399 - 1400
  • [10] The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis
    van Hattum, Jons W.
    de Ruiter, Ben Max
    Oddens, Jorg R.
    de Reijke, Theo M.
    Wilmink, Johanna W.
    Molenaar, Remco J.
    [J]. BLADDER CANCER, 2022, 8 (02) : 211 - 228